| abstract |
A therapeutic agent for a hormone-dependent cancer, whichncomprises (a) a steroid-sulfatase inhibitor and (b) an agentnfor hormone therapy and/or an agent for chemotherapy, whichnmay be administered together or separately at an interval,nis provided. A method for treating a hormone-dependentncancer, which comprises administering (a) a steroid-sulfataseninhibitor and (b) an agent for hormone therapynand/or an agent for chemotherapy together or separately atnan interval, is also provided. A steroid-sulfataseninhibitor which is used in combination with an agent fornhormone therapy and/or an agent for chemotherapy, and whichnis administered together therewith or separately therefromnat an interval, is also provided. A kit for treating anhormone-dependent cancer, which comprises a first componentncomprising (a) a steroid-sulfatase inhibitor and a secondncomponent comprising (b) an agent for hormone therapy and/ornan agent for chemotherapy, is also provided. Anpharmaceutical composition, which comprises (a) a steroid-sulfataseninhibitor and (b) an agent for hormone therapynand/or an agent for chemotherapy, is also provided. Further,nuse of (a) a steroid-sulfatase inhibitor and (b) an agentnfor hormone therapy and/or an agent for chemotherapy for thenmanufacture of a therapeutic agent for a hormone-dependentncancer is provided. |